Cyxone (CYXO.ST) Stock Analysis & AI Equity Report
Cyxone (CYXO.ST) overview
Cyxone (CYXO.ST) stock analysis and AI equity research. For the latest completed financial year, 2023, Cyxone reported revenue of SEK 5.1m and operating profit of SEK -21.7m; the year-end share price was 0.09 SEK and market capitalisation was SEK 9.6m. Cyxone is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Cyxone's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-05. Data will be refreshed during report generation.
About Cyxone
Cyxone AB (publ) is a Swedish clinical-stage biotechnology company developing disease-modifying therapies for immune-related disorders. Its main programs are Rabeximod for rheumatoid arthritis and T20K for multiple sclerosis, supported by a portfolio of immunomodulating drug candidates. The company’s value drivers are clinical development, patent protection, and potential partnering opportunities.
Generate the Cyxone report
Cyxone is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Cyxone and represent the latest completed financial year (2023). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.